4.7 Review

Vaccines for the elderly

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 18, Issue -, Pages 100-108

Publisher

ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2012.03944.x

Keywords

Adjuvant; elderly; herpes zoster; influenza; Streptococcus pneumoniae; travel vaccines; vaccination

Funding

  1. Sanofi Pasteur MSD
  2. Pfizer Inc
  3. Novartis Vaccines
  4. Intercell

Ask authors/readers for more resources

Clin Microbiol Infect 2012; 18 (Suppl. 5): 100108 Abstract Vaccination is the most efficient strategy to prevent infectious disease. The increased vulnerability to infection of the elderly makes them a particularly important target population for vaccination. However, most vaccines are less immunogenic and efficient in the elderly because of age-related changes in the immune system. Vaccination against influenza, Streptococcus pneumoniae and varicella zoster virus is recommended for the elderly in many countries. Various strategies such as the use of adjuvants and novel administration routes are pursued to improve influenza vaccination for the elderly and recent developments in the field of pneumococcal vaccination led to the licensure of protein-conjugated polysaccharide vaccines containing up to 13 serotypes. As antibody titres are generally lower in the elderly andparticularly for inactivated vaccinesdecline fast in the elderly, regular booster immunizations, for example against tetanus, diphtheria and, in endemic areas, tick-borne encephalitis, are essential during adulthood to ensure protection of the elderly. With increasing health and travel opportunities in old age the importance of travel vaccines for persons over the age of 60 is growing. However, little is known about immunogenicity and efficacy of travel vaccines in this age group. Despite major advances in the field of vaccinology over the last decades, there are still possibilities for improvement concerning vaccines for the elderly. Novel approaches, such as viral vectors for antigen delivery, DNA-based vaccines and innovative adjuvants, particularly toll-like receptor agonists, will help to achieve optimal protection against infectious diseases in old age.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available